Literature DB >> 6594972

[Intravesical chemotherapy with 4'-Epi-Adriamycin in patients with superficial bladder tumors].

T Tsushima, Y Matsumura, Y Ozaki, J Yoshimoto, T Obama, T Akagi, Y Nasu, H Ohmori.   

Abstract

Intravesical instillation of anticancer agents is one of the most effective methods for treating superficial bladder cancer. We evaluated the effects of including 4'-Epi-Adriamycin, a derivative of Adriamycin, in intravesical instillation chemotherapy. Thirty-five patients with superficial bladder tumors were treated with 4'-Epi-Adriamycin. The patients received 2 courses of 3 consecutive daily instillations of 50-80 mg 4'-Epi-Adriamycin dissolved in 30 ml of physiological saline, with an interval of 4 days. Of the 33 cases which could be fully evaluated, complete regression was observed in 4 cases and partial regression (greater than 50%) in 14 cases, showing an effectiveness rate of 55%. Side effects such as pollakisuria and miction pain occurred in 9 cases. The rate of effectiveness of this treatment was approximately equivalent to the results that we reported using Adriamycin and the occurrence and degree of side effects were lower.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594972

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

1.  Approaches to the treatment of bladder cancer at Stanford.

Authors:  F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.

Authors:  H Eto; Y Oka; K Ueno; I Nakamura; K Yoshimura; S Arakawa; S Kamidono; S Obe; T Ogawa; G Hamami
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.

Authors:  O Ryoji; H Toma; H Nakazawa; N Goya; T Okumura; T Sonoda; T Kihara; K Tanabe; S Onizuka; H Tomoe
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.

Authors:  K Okamura; T Murase; K Obata; S Ohshima; Y Ono; T Sakata; Y Hasegawa; T Shimoji; K Miyake
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.